DK2409698T3 - Anvendelse af en indazolmethozyalkanonsyre til fremstilling af en farmaceutisk sammensætning - Google Patents
Anvendelse af en indazolmethozyalkanonsyre til fremstilling af en farmaceutisk sammensætning Download PDFInfo
- Publication number
- DK2409698T3 DK2409698T3 DK11185914T DK11185914T DK2409698T3 DK 2409698 T3 DK2409698 T3 DK 2409698T3 DK 11185914 T DK11185914 T DK 11185914T DK 11185914 T DK11185914 T DK 11185914T DK 2409698 T3 DK2409698 T3 DK 2409698T3
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- formula
- pharmaceutical composition
- alkyl
- disease
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 9
- 201000001421 hyperglycemia Diseases 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 6
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 6
- 150000007529 inorganic bases Chemical class 0.000 claims 2
- 150000007530 organic bases Chemical class 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 239000005414 inactive ingredient Substances 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
- MTHORRSSURHQPZ-UHFFFAOYSA-N 2-[(1-benzylindazol-3-yl)methoxy]-2-methylpropanoic acid Chemical compound C12=CC=CC=C2C(COC(C)(C)C(O)=O)=NN1CC1=CC=CC=C1 MTHORRSSURHQPZ-UHFFFAOYSA-N 0.000 description 10
- 229950009949 bindarit Drugs 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 208000008589 Obesity Diseases 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 210000001616 monocyte Anatomy 0.000 description 6
- 235000020824 obesity Nutrition 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000011680 zucker rat Methods 0.000 description 3
- CZMRCDWAGMRECN-UHFFFAOYSA-N 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000011684 zucker rat (obese) Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940098462 oral drops Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Mixers Of The Rotary Stirring Type (AREA)
Claims (12)
1. Anvendelse af en forbindelse med formlen (I):
i hvilken R og R', som kan være ens eller forskellige, er H eller Ci-5 alkyl, og R" er H eller Ci-4 alkyl, valgfrit, når R" er H, i form af et salt deraf med en farmaceutisk acceptabel organisk eller uorganisk base, ved fremstilling af en farmaceutisk sammensætning til behandling af hypertriglyceridemi, hyperkolesterolæmi eller hyperglykæmi.
2. Anvendelse af en forbindelse med formlen (I) ifølge krav 1, i hvilken R" er H og R = R' = CH3.
3. Anvendelse af en forbindelse med formlen (I) ifølge krav 1, i hvilken R" er Na og R = R' = CH3.
4. Anvendelse af en forbindelse med formlen (I) ifølge ethvert af de foregående krav 1 til 3, i hvilken sygdommen er hypertriglyceridemi.
5. Anvendelse af en forbindelse med formlen (I) ifølge ethvert af de foregående krav 1 til 3, i hvilken sygdommen er hyperkolesterolæmi.
6. Anvendelse af en forbindelse med formlen (I) ifølge ethvert af de foregående krav 1 til 3, i hvilken sygdommen er hyperglykæmi.
7. Farmaceutisk sammensætning til anvendelse ved behandling af hypertriglyceridemi, hyperkolesterolæmi eller hyperglykæmi, omfattende en effektiv dosis af mindst en forbindelse med formlen (I):
i hvilken R og R', som kan være ens eller forskellige, er H eller C^s alkyl, og R" er H eller Ci-4 alkyl, valgfrit, når R" er H, i form af et salt deraf med en farmaceutisk acceptabel organisk eller uorganisk base og mindst en farmaceutisk acceptabel inaktiv ingrediens.
8. Farmaceutisk sammensætning til anvendelse ifølge krav 7, i hvilken R" er H, og R = R' = CH3.
9. Farmaceutisk sammensætning til anvendelse ifølge krav 7, i hvilken R" er Na, og R = R' = CH3.
10. Farmaceutisk sammensætning ifølge ethvert af krav 7 til 9, i hvilken syg-dommen er hypertriglyceridemi.
11. Farmaceutisk sammensætning ifølge ethvert af krav 7 til 9, i hvilken syg-dommen er hyperkolesterolæmi.
12. Farmaceutisk sammensætning ifølge ethvert af krav 7 til 9, i hvilken sy9' dommen er hyperglykæmi.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT002254A ITMI20062254A1 (it) | 2006-11-24 | 2006-11-24 | Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca |
| EP07819835A EP2097080B1 (en) | 2006-11-24 | 2007-11-13 | Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2409698T3 true DK2409698T3 (da) | 2015-04-27 |
Family
ID=38198404
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11185914T DK2409698T3 (da) | 2006-11-24 | 2007-11-13 | Anvendelse af en indazolmethozyalkanonsyre til fremstilling af en farmaceutisk sammensætning |
| DK07819835.5T DK2097080T3 (da) | 2006-11-24 | 2007-11-13 | Anvendelse af en indazolmethoxyalkanonsyre til reduktion af triglycerid-, kolesterol- og glukoseniveauer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07819835.5T DK2097080T3 (da) | 2006-11-24 | 2007-11-13 | Anvendelse af en indazolmethoxyalkanonsyre til reduktion af triglycerid-, kolesterol- og glukoseniveauer |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8198310B2 (da) |
| EP (2) | EP2409698B1 (da) |
| JP (1) | JP5192490B2 (da) |
| KR (1) | KR101413616B1 (da) |
| CN (1) | CN101541323B (da) |
| AR (1) | AR063894A1 (da) |
| AU (1) | AU2007323351B2 (da) |
| BR (1) | BRPI0718522A2 (da) |
| CA (1) | CA2666371C (da) |
| CY (1) | CY1116664T1 (da) |
| DK (2) | DK2409698T3 (da) |
| EA (1) | EA016885B1 (da) |
| ES (2) | ES2403584T3 (da) |
| GE (1) | GEP20125570B (da) |
| IL (1) | IL198286A (da) |
| IT (1) | ITMI20062254A1 (da) |
| MX (1) | MX2009004295A (da) |
| PL (2) | PL2409698T3 (da) |
| PT (2) | PT2097080E (da) |
| SG (1) | SG176508A1 (da) |
| SI (2) | SI2097080T1 (da) |
| UA (1) | UA97123C2 (da) |
| WO (1) | WO2008061671A2 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20062254A1 (it) | 2006-11-24 | 2008-05-25 | Acraf | Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca |
| EA019060B1 (ru) | 2009-08-03 | 2013-12-30 | Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А. | Способ получения 1-бензил-3-гидроксиметил-1н-индазола и его производных и необходимые промежуточные соединения с магнием |
| US8999292B2 (en) | 2012-05-01 | 2015-04-07 | Translatum Medicus Inc. | Methods for treating and diagnosing blinding eye diseases |
| ES2789849T3 (es) * | 2014-05-15 | 2020-10-26 | Translatum Medicus Inc | Composiciones y procedimientos para el tratamiento y diagnóstico de trastornos oculares |
| WO2020261158A1 (en) | 2019-06-25 | 2020-12-30 | Translatum Medicus Inc. | Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives |
| JP2023532888A (ja) | 2020-06-27 | 2023-08-01 | クレセンタ バイオサイエンシズ | 細胞代謝を調節する化合物の組成及び使用方法 |
| US12138243B2 (en) | 2021-12-31 | 2024-11-12 | Crescenta Biosciences | Antiviral use of FABP4 modulating compounds |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1131779B (it) * | 1980-07-29 | 1986-06-25 | Acraf | Sale dell'acido (1-benzil-1h-indazol-3-il)-ossiacetico con la lisina e procedimento per la sua preparazione |
| IT1230441B (it) * | 1989-02-07 | 1991-10-23 | Acraf | Eteri della serie dell'indazolo |
| IT1253703B (it) * | 1991-04-22 | 1995-08-23 | Angelini Francesco Ist Ricerca | Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie |
| IT1276031B1 (it) * | 1995-10-31 | 1997-10-24 | Angelini Ricerche Spa | Composizione farmaceutica per il trattamento delle malattie autoimmuni |
| US6077539A (en) * | 1996-11-12 | 2000-06-20 | Pozen, Inc. | Treatment of migraine headache |
| IT1293794B1 (it) | 1997-07-28 | 1999-03-10 | Acraf | Farmaco attivo nel ridurre la produzione di proteina mcp-1 |
| IT1293795B1 (it) | 1997-07-28 | 1999-03-10 | Angelini Ricerche Spa | Farmaco attivo nel ridurre la produzione di proteina mcp-1 |
| EP2583675A1 (en) * | 1998-02-02 | 2013-04-24 | Trustees Of Tufts College | Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism |
| DE19821625C1 (de) * | 1998-05-15 | 2000-01-05 | Merck Patent Gmbh | Pharmazeutische Zubereitung |
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| ITFI20010230A1 (it) * | 2001-11-29 | 2003-05-29 | Menarini Int Operations Lu Sa | Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii |
| US20060030582A1 (en) * | 2002-04-29 | 2006-02-09 | Demartino Julie | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| WO2006117316A1 (en) * | 2005-04-29 | 2006-11-09 | Nycomed Gmbh | Mutual prodrug compounds for use us antiinflammatory agents with gastrointestinal protective activity |
| JP5368801B2 (ja) * | 2005-12-01 | 2013-12-18 | フリンダーズ パートナーズ ピーティワイ リミテッド | 膵炎を予防および／または治療するための方法および組成物 |
| ITMI20062254A1 (it) | 2006-11-24 | 2008-05-25 | Acraf | Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca |
-
2006
- 2006-11-24 IT IT002254A patent/ITMI20062254A1/it unknown
-
2007
- 2007-11-13 SI SI200731208T patent/SI2097080T1/sl unknown
- 2007-11-13 ES ES07819835T patent/ES2403584T3/es active Active
- 2007-11-13 BR BRPI0718522-7A patent/BRPI0718522A2/pt active Search and Examination
- 2007-11-13 PL PL11185914T patent/PL2409698T3/pl unknown
- 2007-11-13 GE GEAP200711327A patent/GEP20125570B/en unknown
- 2007-11-13 CN CN2007800432200A patent/CN101541323B/zh not_active Expired - Fee Related
- 2007-11-13 WO PCT/EP2007/009908 patent/WO2008061671A2/en not_active Ceased
- 2007-11-13 UA UAA200905093A patent/UA97123C2/uk unknown
- 2007-11-13 EP EP11185914.6A patent/EP2409698B1/en not_active Not-in-force
- 2007-11-13 PT PT78198355T patent/PT2097080E/pt unknown
- 2007-11-13 EP EP07819835A patent/EP2097080B1/en not_active Not-in-force
- 2007-11-13 MX MX2009004295A patent/MX2009004295A/es active IP Right Grant
- 2007-11-13 PL PL07819835T patent/PL2097080T3/pl unknown
- 2007-11-13 SI SI200731621T patent/SI2409698T1/sl unknown
- 2007-11-13 DK DK11185914T patent/DK2409698T3/da active
- 2007-11-13 SG SG2011086337A patent/SG176508A1/en unknown
- 2007-11-13 ES ES11185914T patent/ES2530623T3/es active Active
- 2007-11-13 US US12/444,442 patent/US8198310B2/en not_active Expired - Fee Related
- 2007-11-13 KR KR1020097010871A patent/KR101413616B1/ko not_active Expired - Fee Related
- 2007-11-13 DK DK07819835.5T patent/DK2097080T3/da active
- 2007-11-13 AU AU2007323351A patent/AU2007323351B2/en not_active Ceased
- 2007-11-13 EA EA200970506A patent/EA016885B1/ru not_active IP Right Cessation
- 2007-11-13 JP JP2009537517A patent/JP5192490B2/ja not_active Expired - Fee Related
- 2007-11-13 PT PT111859146T patent/PT2409698E/pt unknown
- 2007-11-13 CA CA2666371A patent/CA2666371C/en not_active Expired - Fee Related
- 2007-11-22 AR ARP070105182A patent/AR063894A1/es not_active Application Discontinuation
-
2009
- 2009-04-22 IL IL198286A patent/IL198286A/en active IP Right Grant
-
2012
- 2012-05-08 US US13/466,503 patent/US8846745B2/en not_active Expired - Fee Related
-
2015
- 2015-02-20 CY CY20151100184T patent/CY1116664T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2409698T3 (da) | Anvendelse af en indazolmethozyalkanonsyre til fremstilling af en farmaceutisk sammensætning | |
| JP2018188473A (ja) | 血中グルコースレベルを制御することによる糖尿病及び関連容態の処置のための組成物、方法及び使用 | |
| US12458612B2 (en) | Combination therapy comprising compounds of formula (I) and GLP-1 receptor agonists | |
| WO2000035867A1 (en) | Novel ligands of nuclear receptor | |
| Cao et al. | Advanced glycation end products induced immune maturation of dendritic cells controls heart failure through NF-κB signaling pathway | |
| KR101093930B1 (ko) | 스코파론의 신규 용도 | |
| Qian et al. | Myeloid differential protein-2 inhibition improves diabetic cardiomyopathy via p38MAPK inhibition and AMPK pathway activation | |
| HK1165275B (en) | Use of an indazolemethoxyalkanoic acid to prepare a pharmaceutical composition | |
| HK1129071B (en) | Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels | |
| WO2022215072A2 (en) | Therapeutic modalities for inhibiting pancreatic beta cell impairment and treating diabetes | |
| WO2021146651A1 (en) | Process and compositions for enhancing energy expenditure | |
| WO2014183483A1 (zh) | 一种提高线粒体代谢机能的方法及应用 | |
| WO2008016118A1 (en) | Agent targeting dopamine receptor and screening method therefor | |
| US20250057864A1 (en) | Composition for improving exercise performance comprising gypenoside compound as active ingredient | |
| Yu et al. | METTL3 Potentiates Corneal Allograft Rejection via Increased Pro-Inflammatory Cytokine Production and Aerobic Glycolysis | |
| KR101349185B1 (ko) | 지방대사 이상질환의 치료 및 예방용 약학 조성물 | |
| Grujic et al. | 1639: Oral Therapy with Crystalline Formulation of Oxalate Degrading Enzvme in Rodent Models with Hyperoxaluria | |
| JP2015027968A (ja) | エタノールアミンリン酸の利用 |